Abstract: A method of preparing a medicament for a treatment of anemia includes the step of using an antiplatelet thrombolysin in preparing the medicament, and the antiplatelet thrombolysin has an activity of improving the anemia. The antiplatelet thrombolysin consists of two peptide chains of ? chain and ? chain, in which the ? chain amino acid sequence is shown in SEQ ID NO: 1, the ? chain amino acid sequence is shown in SEQ ID NO: 2; or the antiplatelet thrombolysin is derived from the ? chain amino acid sequence by substitution, deletion, or addition of one or more amino acids and has at least 95% identity with SEQ ID NO: 1; or the antiplatelet thrombolysin is derived from the ? chain amino acid sequence by substitution, deletion, or addition of one or more amino acids and has at least 95% identity with SEQ ID NO: 2.

Abstract: A method of preparing a medicament for inhibiting an inflammation includes the step of using an antiplatelet thrombolysin. The antiplatelet thrombolysin consists of two peptide chains of ? chain and ? chain, and the ? chain amino acid sequence is shown in SEQ ID NO:1, ? chain the amino acid sequence is shown in SEQ ID NO: 2; or the antiplatelet thrombolysin is derived from the ? chain amino acid sequence by substitution, deletion, or addition of one or more amino acids and has at least 95% identity with SEQ ID NO: 1, or the antiplatelet thrombolysin is derived from the ? chain amino acid sequence by substitution, deletion, or addition of one or more amino acids and has at least 95% identity with SEQ ID NO: 2; and the antiplatelet thrombolysin has an activity of inhibiting the inflammation.

Abstract: Provided are recombinant plasmids containing the gene of the heterodimeric snake venom protein Agkisacutacin A chain and Agkisacutacin B chain, cell strains containing the recombinant plasmids, and a method for expressing the heterodimeric snake venom protein Agkisacutacin. The expression level of Agkisacutacin in the present method exceeds 10 mg/L, and the purity level can reach more than 95% by means of two steps of purification.

Abstract: A method and pharmceutical compositon for the treatment of thrombotic thrombocytopenic purpura. The method and pharmceutical compositon uses a therapuetically effective amount of an antiplatelet thrombolysin comprising two polypeptide chains, an alpha chain and a beta chain. The antiplatelet thrombolysin of the invention can limit platelet adhesion and aggregation, restore platelets, red blood cell and hemoglobin levels, at the same time, reduce the level of lactate dehydrogenase, and effectively inhibits thrombocytopenia and schistocyte hemolytic anemia, so as to achieve the purpose of the treatment of TTP, which has a good prospect of clinical use.